- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11.25 | NSE - LakeShore Biopharma Co., Ltd. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| 04.11.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.09.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.09.2025 | 988 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 30.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.09.2025ISIN NameCA8875221001 TINKA... ► Artikel lesen | |
| LAKESHORE BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 22.09.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting | 213 | PR Newswire | BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 12.09.25 | LakeShore Biopharma faces Nasdaq delisting after failing to meet bid price rule | 2 | Investing.com | ||
| 12.09.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq | 848 | PR Newswire | BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 10.09.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.09.25 | LakeShore Biopharma appoints advisors to evaluate buyout proposal | 1 | Investing.com | ||
| 29.08.25 | LakeShore Biopharma Board Reviewing Revised $0.86-Per-Share Buyout Proposal | - | RTTNews | ||
| 28.08.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee | 503 | PR Newswire | BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 18.08.25 | LakeShore Biopharma receives $0.86/share buyout proposal from Oceanpine Capital | 2 | Seeking Alpha | ||
| 18.08.25 | LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.08.25 | Oceanpine Capital unterbreitet Übernahmeangebot für LakeShore Biopharma zu 0,86 US-Dollar je Aktie | 1 | Investing.com Deutsch | ||
| 18.08.25 | Oceanpine Capital proposes to acquire LakeShore Biopharma for $0.86 per share | 1 | Investing.com | ||
| 18.08.25 | LakeShore Biopharma Receives Proposal Letter From Oceanpine Capital | 1 | RTTNews | ||
| 18.08.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company | 194 | PR Newswire | BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company... ► Artikel lesen | |
| 01.08.25 | LakeShore Biopharma GAAP EPS of -RMB5.22, revenue of RMB615M | 1 | Seeking Alpha | ||
| 31.07.25 | LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Fiscal Year 2025 Financial Results | 116 | PR Newswire | Total revenue reached RMB615.0 million, representing 7.2% year-over-year growth
Gross profit rose to RMB507.2 million, up 11.3% year-over-year
Gross margin improved... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DYNE THERAPEUTICS | 17,450 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 40,690 | +0,68 % | XFRA NEW INSTRUMENTS AVAILABLE ON 08.01.2026 | The following instruments on XETRA do have their first trading 08.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.01.2026
Aktien
1 US75974A1016 RENK Group AG ADR
2... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,850 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| ARCELLX | 69,86 | +4,66 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| BEAM THERAPEUTICS | 35,410 | +2,49 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| CG ONCOLOGY | 55,51 | 0,00 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,280 | +3,28 % | ADMA Biologics, Inc. (ADMA): A Bull Case Theory | ||
| APOGEE THERAPEUTICS | 82,43 | +4,34 % | Apogee Therapeutics auf Rekordhoch: Aktie erreicht 81,0 USD | ||
| HARMONY BIOSCIENCES | 36,040 | +0,78 % | Harmony Biosciences: WAKIX-Umsatz soll 2026 die Marke von 1 Milliarde US-Dollar übersteigen | ||
| BIONTECH | 93,60 | -0,11 % | BioNTech SE: BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026 | 2026 soll für BioNTech ein Jahr mit zahlreichen wertrelevanten Meilensteinen (Katalysatoren) werden, unter anderem durch weitere Fortschritte bei Pipeline-Kandidaten, die sich bereits in der späten... ► Artikel lesen | |
| NUVALENT | 107,84 | 0,00 % | Nuvalent, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 84,09 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ERASCA | 8,320 | 0,00 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 297,90 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| ALUMIS | 24,330 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen |
Das Unternehmen LAKESHORE BIOPHARMA CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,665 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKESHORE BIOPHARMA CO LTD finden Sie auf Wallstreet Online.